Eric Tran, Ph.D.

Rom Leidner, M.D.

Providence Cancer Institute is among a handful of centers in the world capable of developing a type of cancer immunotherapy called adoptive cell therapy.

Under the leadership of Eric Tran, Ph.D., and Rom Leidner, M.D., our team has pioneered a second-generation adoptive cell therapy using genetically engineered T cells, a type of immune cell capable of destroying cancer cells.

Their innovative work is published in the New England Journal of Medicine article Neoantigen T-Cell Receptor-Gene Therapy in Pancreatic Cancer available in the June 2, 2022, issue.

Philanthropy funds more than 70% of our cancer research. This work would not be possible without the generous support of donors and the participation of patients whom we are privileged to serve. Thank you.

Give Now